Management of immune-related adverse events and kinetics of response with ipilimumab.
about
Toxicity management of immunotherapy for patients with metastatic melanomaImmunobiology and immunotherapy in genitourinary malignanciesMelanoma immunotherapy dominates the fieldThe European Organization for Research and Treatment of Cancer perspective on designing clinical trials with immune therapeuticsNew targeted treatments for non-small-cell lung cancer - role of nivolumabInhibiting Immune Checkpoints for the Treatment of Bladder CancerAdvances in immunotherapy for melanomaNovel Drugs and Combination Therapies for the Treatment of Metastatic MelanomaImmune checkpoint inhibitors in clinical practice: update on management of immune-related toxicitiesLong-term survival as a treatment benchmark in melanoma: latest results and clinical implicationsOverview of current immunotherapeutic strategies for gliomaCTLA-4 and PD-1 Pathways: Similarities, Differences, and Implications of Their InhibitionCancer-treatment-induced neurotoxicity--focus on newer treatmentsImmune Checkpoint Blockade: A New Paradigm in Treating Advanced CancerImmune Effects of Chemotherapy, Radiation, and Targeted Therapy and Opportunities for Combination With ImmunotherapyImmune checkpoint inhibitor therapy associated hypophysitisNew modalities of cancer treatment for NSCLC: focus on immunotherapyImmune Checkpoint Blockade in Cancer TherapyPD-1 as an emerging therapeutic target in renal cell carcinoma: current evidenceImmunotherapy advances for glioblastomaReview of immune-related adverse events in prostate cancer patients treated with ipilimumab: MD Anderson experienceTreatment possibilities of ipilimumab-induced thrombocytopenia--case study and literature reviewToxicities of Immunotherapy for the PractitionerUpdate on benefit of immunotherapy and targeted therapy in melanoma: the changing landscape.The price of tumor control: an analysis of rare side effects of anti-CTLA-4 therapy in metastatic melanoma from the ipilimumab networkAdverse Events Associated with Immune Checkpoint Blockade in Patients with Cancer: A Systematic Review of Case ReportsImmune-related ocular toxicities in solid tumor patients treated with immune checkpoint inhibitors: a systematic review.Systemic therapy for bladder cancer finally comes into a new age.Autoimmune-like drug-induced liver injury: a review and update for the clinician.Current and future directions in the treatment and prevention of drug-induced liver injury: a systematic review.Maintenance treatment with the immunomodulator MGN1703, a Toll-like receptor 9 (TLR9) agonist, in patients with metastatic colorectal carcinoma and disease control after chemotherapy: a randomised, double-blind, placebo-controlled trial.Clinical experience with ipilimumab 3 mg/kg: real-world efficacy and safety data from an expanded access programme cohort.Management of immune checkpoint blockade dysimmune toxicities: a collaborative position paper.Thrombocytopenia in patients with melanoma receiving immune checkpoint inhibitor therapy.New drugs, new toxicities: severe side effects of modern targeted and immunotherapy of cancer and their management.Vedolizumab treatment for immune checkpoint inhibitor-induced enterocolitis.Clinical experience with ipilimumab 10 mg/kg in patients with melanoma treated at Italian centres as part of a European expanded access programme.Opportunistic Autoimmune Disorders Potentiated by Immune-Checkpoint Inhibitors Anti-CTLA-4 and Anti-PD-1Inflammatory Arthritis: A Newly Recognized Adverse Event of Immune Checkpoint BlockadeT-Cell Therapy Using Interleukin-21-Primed Cytotoxic T-Cell Lymphocytes Combined With Cytotoxic T-Cell Lymphocyte Antigen-4 Blockade Results in Long-Term Cell Persistence and Durable Tumor Regression
P2860
Q26738662-C5D3E847-2FCB-453C-990F-19530502EFE0Q26738668-0AE76973-78EF-4981-A471-30B815EFC26DQ26738671-45F30D89-A96E-4391-B764-8F0B7C9BB9FBQ26738677-AC82EBC3-1B4E-4EE1-9907-5FDBEFB774B0Q26740988-C26960FF-AADD-4D03-A9F2-E9245D6C2ECEQ26744758-6D2FDDD5-AA5D-4991-8F3D-8E7A32D128AEQ26768558-B542C3E3-4218-4715-80C1-488DE5933787Q26772015-3FF2AD60-01C2-4DD9-B2F8-A2EDFC60F8BDQ26775383-2FEE581A-335D-4169-8E3A-AA70230DCC4FQ26775546-E1EF720D-9136-4007-95D7-7155A5A98537Q26776345-CEFFC841-80DA-4DD3-8405-D1604902A8A7Q26777563-EF0D4BB3-6811-4991-BB64-8FA2D4AD03CAQ26782604-77D59965-770B-42DA-918C-CF02ABD318B3Q26795509-FD7E3CEA-7EB3-481A-BB0F-F91958910373Q26796309-FF0AA601-6739-485A-BBAB-915BA89005A2Q26827140-B438296E-5C02-474E-AF18-C13DDD95EA06Q26829161-75B28BA8-B15A-415C-BAD4-D034F292D302Q26830509-CBD9C884-EA91-497E-93B2-30F0F5C8A37BQ26865789-43A32EA8-9939-4174-B6BA-1F846F5B0C3AQ26866513-767A56A4-97B5-457B-B46F-040CA9652389Q26995499-A15C6AD9-0D58-47CF-BEA5-7CFC5C3B06F5Q26999394-C43E1171-765C-4C9A-87B3-680D30834383Q27008140-B0AA4959-FB1C-4EB0-98C4-2F3B3DA49A28Q27691824-9222F46D-7AED-4783-B375-3020F7C5151FQ28485085-7C17F4D6-DA41-4F5D-84F0-40F2FACC89F2Q28553328-7650949C-6CD2-4ED5-B382-6BD87B8079B4Q30235360-BCF23D71-A863-4919-A93F-DC13B9716B0EQ30249047-D2D62F2F-42A9-4FFA-9446-5DEECA595B3BQ30276377-33C5D080-9978-4992-AC7A-B7C24B2C20A8Q30277969-1D41D155-5928-460D-A9F7-81F403A656B9Q30317446-A7FE0082-C3C6-4E38-812F-82B1417319CDQ30828178-BE1ACB6E-2802-4378-92CC-013E5ECB73F6Q31034415-9FEC181B-C9F6-4CB5-833B-54A3D2BB7F88Q33439649-F405E12A-FDC1-4C18-A774-07204F0E1EE2Q33564645-89E439E3-0313-4E78-8AF8-A22F9D929CDEQ33607108-E3A1A801-247C-49B1-AA02-01FA0C6187C9Q33643902-A0E4B722-6581-46B7-8685-74686D0E95ABQ33658400-E306EB44-9587-4655-AE3C-1345DD938EB9Q33793552-1C5EE07B-90AC-466D-B66B-94A01D94BEE2Q33816848-F3E619F3-1A17-4C5B-8A82-8F3F580E91E0
P2860
Management of immune-related adverse events and kinetics of response with ipilimumab.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Management of immune-related adverse events and kinetics of response with ipilimumab.
@en
type
label
Management of immune-related adverse events and kinetics of response with ipilimumab.
@en
prefLabel
Management of immune-related adverse events and kinetics of response with ipilimumab.
@en
P2093
P356
P1476
Management of immune-related adverse events and kinetics of response with ipilimumab.
@en
P2093
Axel Hauschild
Jeffrey S Weber
Katharina C Kähler
P304
P356
10.1200/JCO.2012.41.6750
P407
P577
2012-05-21T00:00:00Z